Biokin's EGFR-HER3 bispecific ADC succeeds in late-stage Chinese lung cancer trial
Chinese biotech Biokin announced that its EGFRxHER3 bispecific antibody-drug conjugate met its primary endpoint in a late-stage trial in a genetically defined subset of non-small cell lung cancer (NSCLC) conducted in China.
The trial results, which showed a statistically significant improvement in efficacy measures, are expected to support a parallel global study being run by partner Bristol Myers Squibb, raising hopes for broader regulatory submissions.
The positive outcome adds momentum to the development of bispecific ADCs targeting EGFR and HER3, and investors are watching the upcoming data from the global trial for further validation.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that